35Pharma Oral Presentation at ObesityWeek 2025: HS235 Demonstrates Activity in Pre-Clinical Models of Obesity and Heart Failure.

Pre-clinical data demonstrate that HS235 effectively addresses major hallmarks of Heart Failure with preserved Ejection Fraction (HFpEF) Data supports ongoing HS235 Phase 1b clinical trials in obese patients with Pulmonary Hypertension due to HFpEF (NCT07123779) as well as in patients suffering from Pulmonary Arterial Hypertension (NCT07143448) Montreal, QC, Canada (Nov 4, 2025) 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today presented pre-clinical HS235 data during an oral presentation at ObesityWeek 2025 in Atlanta, GA. HS235 is a next-generation BMP-9/-10 sparing Activin Signaling Inhibitor being investigated in patients with pulmonary hypertension. HS235 was engineered to achieve higher potency against Activin and Growth Differentiation Factor ligands while sparing BMP-9/-10 ligands whose neutralization has been associated with bleeding, telangiectasia and pericardial effusions. During the oral presentation, Maureen O’Connor, Ph.D., Chief Scientific Officer of 35Pharma, presented pre-clinical data demonstrating that HS235 effectively addresses major hallmarks of HFpEF by: Selectively decreasing fat mass, including pericardial adipose tissue; Improving the synthesis of adipokines yielding a metabolically more favourable profile; and Reversing cardiac hypertrophy and rescuing left ventricular function. Collectively, these data support HS235’s differentiated profile and potential to address both cardio-pulmonary remodeling as well as metabolic dysfunction. Two Phase 1b clinical trials have been initiated to evaluate HS235 in patients with obesity and Pulmonary Hypertension due to HFpEF (PH-HFpEF, Group 2 PH) and patients with Pulmonary Arterial Hypertension (PAH, Group 1 PH). ‍

The release as fetched from its publisher. 35pharma.com ↗